The atezolizumab market comprises monoclonal antibody drugs that target programmed death ligand-1 (PD-L1) and are used for treating various types of cancer. Atezolizumab works by binding to PD-L1 receptors present on tumor cells and inhibiting interactions between PD-L1 and its receptors PD-1 and B7.1 that are found on T cells. This enables the activation of T cells to attack cancer cells and...
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian